Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genotyping Natural Killer Immune Checkpoints to Discover Biomarkers of Response.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jan 2018

Cheung Nai-Kong, Hsu Katharine C

Abstract excerpt

Immune checkpoints have been a focus of immunotherapy in the recent decade. Killer cell immunoglobulin-like receptors (KIR) and their cognate human leukocyte antigen (HLA) class I ligands have evolved as checkpoints to ensure self-tolerance of natural killer cells. Both KIR and HLA genetic profiles are potential biomarkers of immunotherapy outcome. Clin Cancer Res; 24(1); 3-5. ©2017 AACRSee related article by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Biomarkers

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HLA-C Antigens

Share to Immunotherapy

Share to Killer Cells, Natural

Share to Ligands

Share to Neuroblastoma

Share to Receptors, KIR

Source

Open in PubMed Open full text

Identifiers

PMID: 29122934
DOI: 10.1158/1078-0432.CCR-17-2884
PMCID: PMC5754255

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genotyping Natural Killer Immune Checkpoints to Discover Biomarkers of Response.PMID 29122934Read ↗

HLA genotyping meets response to immune checkpoint inhibitors prediction: A story just started.Semantic proximity Read ↗

Immune checkpoints and cancer in the immunogenomics eraSemantic proximity Read ↗

Can we make a better match or mismatch with KIR genotyping?Semantic proximity Read ↗

HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study.Semantic proximity Read ↗

Killer Ig-Like Receptors (KIRs): Their Role in NK Cell Modulation and Developments Leading to Their Clinical ExploitationSemantic proximity Read ↗

Allelic polymorphisms of KIRs and antitumor immunity against chronic myeloid leukemia.Semantic proximity Read ↗

Pan-Cancer HLA Gene-Mediated Tumor Immunogenicity and Immune EvasionSemantic proximity Read ↗

Allelic Polymorphisms of KIRs and HLAs Predict Favorable Responses to Tyrosine Kinase Inhibitors in CML.Semantic proximity Read ↗

Association of Germline Variants in Natural Killer Cells With Tumor Immune Microenvironment Subtypes, Tumor-Infiltrating Lymphocytes, Immunotherapy Response, Clinical Outcomes, and Cancer RiskSemantic proximity Read ↗

Review – The impact of pharmacogenetics on the outcome of immune checkpoint inhibitorsSemantic proximity Read ↗

Risk assessment of cancer patients based on HLA-I alleles, neobinders and expression of cytokines.Semantic proximity Read ↗

Natural killer cell educating KIR/HLA combinations impact survival in anti-PD-L1 treated cancer patientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.